For decades, advances in health and health care have had a bias toward the male body. By shifting the focus of research to women's bodies and building out this base of evidence on women's health, scientists and doctors can improve health outcomes and overall quality of life for women, all while also saving money.
The authors find that small investments are likely to yield large gains from increasing research funding in rheumatoid arthritis; investing in women's health research yields benefits above investing in general research.
The potential gains from women-focused research are substantial, given the limitations in knowledge about disease development and impacts for women relative to men. Savings would include increased life years, fewer disruptions to work productivity, and fewer years with disease and functional dependence.
The core elements in the Canadian Rheumatoid Arthritis Core Clinical Dataset were rated as important and feasible to collect by rheumatology care providers and people living with arthritis from across Canada.
This study aims to develop system-level performance measures for evaluating the care of patients with inflammatory arthritis (IA), including rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis.
Given the broad scope of the spillover effects of illness, it is important to characterize the variability in these outcomes to identify relationship types in which secondary impacts of illness are particularly important to include in health economic evaluations.
Patients with multi-morbid diabetes, arthritis, neurological, or long-term mental health problems have significantly lower health-related quality of life (HRQoL) than other people. The associations of physical health with HRQoL were stronger in the presence of long-term mental health problems.
Estimates the minimally important difference for a fatigue visual analog scale (VAS) using patient-reported anchors (fatigue, pain, and overall health). This information can aid in interpreting fatigue VAS in day-to-day care in clinical practice.
The authors conducted a prospective cohort study of rates of change in disease-modifying antirheumatic drug (DMARD) and/or systemic corticosteroid drug or dose for 568 patients with rheumatoid arthritis (RA) across 6,159 clinical encounters within 12 months to examine how changes in clinical specifications change adherence.